Aims/Purpose: Basal cell carcinoma (BCC) is the most common type of tumor worldwide. Although it has a low capacity for systemic spread, it exhibits a high rate of local invasion. The most frequently affected areas are the face and neck. So far, the most widely used treatment has been surgery in its various forms: excision‐electrodesiccation‐curettage, cryotherapy, or the increasingly common Mohs micrographic surgery. In recent years, various researchers have identified molecules that can reduce or even eliminate these lesions. Among them, we highlight Vismodegib due to the good results obtained. This molecule is the first selective Hedgehog pathway inhibitor approved for the treatment of local and metastatic BCC.Methods: A 57‐year‐old female patient came to our clinic, referred by the dermatology department of our hospital, due to a basal cell carcinoma on the left lower eyelid affecting the free margin.Results: An incisional biopsy of the lesion was performed, diagnosing nodular BCC. After explaining the characteristics of the tumor and the therapeutic options to the patient, it was decided to start treatment with Vismodegib, include her in the surgical waiting list, and perform monthly follow‐up. In subsequent check‐ups, the patient reported good tolerance and adherence to the treatment, without adverse side effects. During the consultations, a clear reduction of the lesion was observed. However, due to the incomplete disappearance of the lesion, it was decided to perform a wedge resection of the tumor.Conclusions: Currently, the patient shows a good alignment of the free margin, with good tension and no signs of tumor activity.
Read full abstract